NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer
A four-drug chemotherapy combination built on liposomal irinotecan extended survival in metastatic pancreatic cancer by about two months compared with the most widely used doublet, the first positive first-line trial in a decade.
Open-label phase 3 trial of 770 patients with untreated metastatic pancreatic adenocarcinoma randomised to NALIRIFOX (liposomal irinotecan, oxaliplatin, fluorouracil, leucovorin) or gemcitabine plus nab-paclitaxel. Primary endpoint was overall survival.
Median OS was 11.1 vs 9.2 months (HR 0.83) and median PFS 7.4 vs 5.6 months (HR 0.69). It was the first randomised evidence that a FOLFIRINOX-type regimen beats gemcitabine plus nab-paclitaxel, and led to FDA approval of NALIRIFOX in 2024, though conventional FOLFIRINOX remains the usual choice where it is affordable.
- Median overall survival 11.1 vs 9.2 months; HR 0.83 (95% CI 0.70-0.99).
- Median PFS 7.4 vs 5.6 months; HR 0.69 (95% CI 0.58-0.83).
- Objective response 41.8% vs 36.2%.
- Grade 3-4 diarrhoea 20% vs 5% and grade 3-4 neutropenia lower with NALIRIFOX (14% vs 25%); peripheral neuropathy less frequent with NALIRIFOX.
- Benefit was consistent across age groups but the trial enrolled fit patients (ECOG 0-1).
For fit patients with newly diagnosed metastatic pancreatic cancer, a FOLFIRINOX-type regimen is now proven to be better than gemcitabine plus nab-paclitaxel, settling a long-standing debate. The absolute gain is about two months of median survival, and the regimen is more toxic for the gut. Whether liposomal irinotecan adds anything over conventional irinotecan (standard FOLFIRINOX) has never been tested head-to-head.
- No direct comparison with standard FOLFIRINOX, which is much cheaper; the benefit of the liposomal formulation is inferred, not shown.
- Absolute survival gain is modest and the population was fit and relatively young (median 65).
- Open-label design.
- Highlights how little progress systemic therapy has made in pancreatic cancer: median survival remains under a year.
Pages like this
not linked directly; found by shared links- ProductNALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)
Shares Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Cytotoxic chemotherapy, Pancreatic ductal adenocarcinoma.
- Key paperKEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation
Shares Lines of therapy, Platinum agents, Overall survival (OS), Progression-free survival (PFS).
- Key paperKEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer
Shares Standard of care, Platinum agents, Overall survival (OS), Progression-free survival (PFS).
- Key paperADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer
Shares Standard of care, Platinum agents, Overall survival (OS), Progression-free survival (PFS).
- Key paperKEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer
Shares Lines of therapy, Platinum agents, Overall survival (OS), Progression-free survival (PFS).
- IdeaProvisional prices for surrogate-endpoint approvals, reset when survival data arrive
Shares Overall survival (OS), Progression-free survival (PFS), Prices and value.
- Key paperPACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer
Shares Standard of care, Platinum agents, Overall survival (OS), Progression-free survival (PFS).
- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Platinum agents, Prices and value, Cytotoxic chemotherapy.